Articles
Tunnah’s musings: why the drug industry is finished

Tunnah’s musings: why the drug industry is finished

In his latest musings Paul Tunnah thinks it’s time to draw a line under the drug industry, as it’s clearly got no future in the management of disease and delivery of health. Last week I was surprised and, I have to admit, a little flattered to discover that I was the number one #pharmasuperfan, as determined by Silja Chouquet in…

Articles
Pharma and Facebook’s face off: why does the industry want to be on Facebook?

Pharma and Facebook’s face off: why does the industry want t...

Darshan Kulkarni questions why the industry is so keen to be on Facebook and how explores how pharma can remain active on Facebook despite regulatory hurdles. Facebook has 750 million active users. 50% of those active users log onto Facebook everyday. The average user has 130 friends. Individuals spend over...

Articles
Pharma gets social: social mobile app helps Pfizer engage consumers in Israel

Pharma gets social: social mobile app helps Pfizer engage co...

This month in 'Pharma gets social', Daniel Ghinn takes a look at Pfizer’s mobile health app for those with overactive bladders. Social mobile app connects Pfizer with the right patients in the right place! There are no other emerging digital channels that capture the…

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. UK budget includes £1bn biopharma investment package
  2. HHS doubles down on controversial peptides plan
  3. Lilly's triple G overpowers Ozempic in diabetes trial
  4. UK puts £100m into "world-first" AI biosecurity facility
  5. US gives $99m for Ebola jab project, as cases spread in Africa

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more